Microneedling Alone vs Microneedling With PRP in the Treatment of Macular Amyloidosis; a Split Face Comparative Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: microneedling, microneedling with PRP.
- Who it may be relevant to
- Registry conditions: Macular Amyloidosis. Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Comparison Between Efficacy and Safety of PRP With Microneedling and Microneedling Alone in Treatment of Macular Amyloidosis; a Split Face Blinded Non Randomized Control Trial With Dermoscopic and Histopathologic Evaluation
Overview
This study is going to asses and compare the efficacy of treatment of macular amyloidosis using microneedling vs PRP with microneedling. Pruritus and pigmentation will be assessed.
Interventions
- Device microneedling
microneedling will be done for the one arm of macular amyloidosis - Device microneedling with PRP
microneedling with PRP will be done on macular amyloidosis
Primary outcome measures
- Improvement of macular amyloidosis using microneedling or PRP with microneedling [Time frame: 3 months]
Eligibility criteria
Inclusion Criteria: • Both genders were included.
- Patients above 18 years old.
- Patients diagnosed by macular amyloidosis, proved by dermoscopy and histopathology.
Exclusion Criteria: • Prior use of topical therapies in the previous 4 weeks.
- Prior use of any procedures such as chemical peel or laser treatment in the previous 1 month.
- Prior use of any systemic treatment for macular amyloidosis in the past 12 weeks.
- Patients with other skin conditions (e.g., psoriasis, eczema).
- Immunocompromised patients (HIV, chemotherapy).
- Patients with history of any type of autoimmune disorders, coagulopathies, and keloid tendency.
- Known or suspected allergy to ingredients
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Non-randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07360860 · MS-59-2025